SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules.
Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.
Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their R&D goals
Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.
Syngene has taken an important step forward in its contribution towards protecting the planet. We have committed to Science Based Targets (SBTi) which will involve reducing our greenhouse gas (GHG) emissions by 50% by 2033 to align with the Paris Agreement limiting global warming to 1.5°C. With this initiative, Syngene joins the group of over 7000 companies taking action by setting emissions reduction targets in line with climate science.
© 2025. Syngene International Limited